Celularity Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 3850 www.celularity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc.

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors - May 6th, 2026 7:00 am
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - May 1st, 2026 2:30 pm
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Apr 27th, 2026 7:00 am
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Apr 21st, 2026 7:00 am
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Apr 21st, 2026 6:30 am
Celularity Announces Closing of Transaction with NexGel - Apr 21st, 2026 6:30 am
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - Apr 17th, 2026 2:35 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 15th, 2026 2:12 pm
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - Apr 8th, 2026 2:05 pm
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - Mar 31st, 2026 2:12 pm
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 12th, 2026 6:45 am
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities - Mar 12th, 2026 6:30 am
Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board - Mar 12th, 2026 1:33 am
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - Mar 10th, 2026 6:45 am
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy - Mar 10th, 2026 6:30 am
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses - Feb 10th, 2026 6:30 am
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations - Dec 26th, 2025 6:30 am
Celularity Announces Closing of Financing Transactions - Dec 22nd, 2025 2:01 pm
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision - Dec 18th, 2025 12:10 pm
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - Oct 30th, 2025 6:00 am